WO2009067600A2 - Inhibiteurs de pde4 biaryle pour traiter une inflammation - Google Patents

Inhibiteurs de pde4 biaryle pour traiter une inflammation Download PDF

Info

Publication number
WO2009067600A2
WO2009067600A2 PCT/US2008/084193 US2008084193W WO2009067600A2 WO 2009067600 A2 WO2009067600 A2 WO 2009067600A2 US 2008084193 W US2008084193 W US 2008084193W WO 2009067600 A2 WO2009067600 A2 WO 2009067600A2
Authority
WO
WIPO (PCT)
Prior art keywords
nhc
mmol
alkyl
chosen
compound
Prior art date
Application number
PCT/US2008/084193
Other languages
English (en)
Other versions
WO2009067600A3 (fr
Inventor
Jasbir Singh
Mark E. Gurney
Alex Burgin
Vincent Sandanayaka
Alexander Kiselyov
Adalie Motta
Gary Schultz
Georgeta Hategan
Timothy Hagen
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Priority to CA2722582A priority Critical patent/CA2722582A1/fr
Priority to EP08851045A priority patent/EP2222638A2/fr
Priority to CN2008801251758A priority patent/CN102089279A/zh
Priority to JP2010535064A priority patent/JP2011505341A/ja
Priority to PCT/US2008/084193 priority patent/WO2009067600A2/fr
Priority to AU2008326381A priority patent/AU2008326381B2/en
Publication of WO2009067600A2 publication Critical patent/WO2009067600A2/fr
Publication of WO2009067600A3 publication Critical patent/WO2009067600A3/fr
Priority to IL205881A priority patent/IL205881A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/58—Y being a hetero atom
    • C07C275/62—Y being a nitrogen atom, e.g. biuret
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
    • C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/10—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present invention relates to a chemical genus of biaryl inhibitors of phosphodiesterase-4 (PDE4) useful for the treatment and prevention of stroke, myocardial infarct, cardiovascular inflammatory diseases and central nervous system disorders.
  • PDE4 phosphodiesterase-4
  • PDE4 is the major cAMP-metabolizing enzyme found in inflammatory and immune cells.
  • PDE4 inhibitors have proven potential as anti- inflammatory drugs, especially in inflammatory pulmonary diseases such as asthma, COPD and rhinitis. They suppress the release of cytokines and other inflammatory signals and inhibit the production of reactive oxygen species.
  • a large number of PDE4 inhibitors have been developed for a variety of clinical indications (Torphy and Page. 2000. TIPS 21, 157- 159; Burnouf and Pruniaux. 2002. Curr. Pharm. Design 8, 1255-1296; Lipworth. 2005. Lancet 365, 167-175).
  • PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications.
  • COPD chronic obstructive pulmonary disease
  • PDE4 inhibitors of various structural classes including cilomilast, filaminast, lirimilast, piclamilast, tofimilast has been discontinued due to lack of efficacy.
  • a primary problem is the low therapeutic ratio of these compounds, which severely limits the dose that can be given.
  • the compounds of the present invention are non-competitive inhibitors of cAMP while being gene-specific inhibitors (PDE4D), and, based on the target rationale and in vitro potency, a person of skill in the art would expect the compounds to be useful as anti- inflammatory agents for the treatment, amelioration or prevention of inflammatory diseases and of complications arising therefrom and useful as CNS agents for amelioration of the cognitive decline in Alzheimer's disease, Parkinson's disease, the treatment of schizophrenia and depression, and neuroprotective in Huntington's disease.
  • PDE4D gene-specific inhibitors
  • the present invention relates to compounds exhibiting PDE4 enzyme inhibition, having the general formula I
  • R 1 is an optionally substituted carbocycle or optionally substituted heterocycle of three or fewer rings;
  • R 2 is an optionally substituted carbocycle or optionally substituted heterocycle of two or fewer rings;
  • R 3 is chosen from H, -C(O)NH 2 , -(C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, -(Ci-C 6 )alkyl-R 30 ,
  • R 31 is chosen from (Ci-C/Oalkoxy, amino, hydroxy, (Ci-C6)alkylamino and di(Ci-
  • R 4 is chosen from H and F;
  • R 6 is chosen from H, (Ci-Ce)alkyl and halogen;
  • X is N, N ⁇ O, or C-R 5 ;
  • RR 55 iiss cchhoosseenn ffrroomm HH,, hhaallogen, OH, (C 1 -C 6 )alkyl, (d-C 6 )alkoxy, CF 3 , CN, NH 2 ,
  • n is zero, one or two; and R 20 , R 21 and R 22 are selected independently in each occurrence from H and (Ci-C/Oalkyl.
  • the present invention also relates to two subgenera of compounds of formula I.
  • the present invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of the general formula I described above.
  • the salt should be a pharmaceutically acceptable salt.
  • the invention relates to methods for the treatment or prophylaxis of a disease or condition mediated by phosphodiesterase-4.
  • the methods comprise administering to a mammal a therapeutically effective amount of a compound having the general formula I.
  • the disease or condition may be related to allergic, acute or chronic inflammation.
  • the disease may be, for example, atherosclerosis, thrombosis, stroke, acute coronary syndrome, stable angina, peripheral vascular disease, critical leg ischemia, intermittent claudication, abdominal aortic aneurysm or myocardial infarction.
  • Selective PDE4 inhibitors of the invention are expected to be useful in improving cognition and thus useful for treating learning disorders, memory loss and other cognitive dysfunctions.
  • Selective PDE4 inhibitors of the invention are also useful for treating asthma and Chronic Obstructive Pulmonary Disease (COPD).
  • COPD Chronic Obstructive Pulmonary Disease
  • Compounds of the invention, which inhibit tumor growth and metastases, also find utility in the treatment and prevention of cancer, including esophageal cancer, brain cancer, pancreatic cancer, and colon cancer.
  • alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. A combination would be, for example, cyclopropylmethyl.
  • Lower alkyl refers to alkyl groups of from 1 to 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl and the like. Preferred alkyl groups are those of C 2 0 or below; Ci to Cg are more preferred.
  • Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c- pentyl, norbornyl and the like.
  • Ci to C 20 hydrocarbon includes alkyl, cycloalkyl, polycycloalkyl, alkenyl, alkynyl, aryl and combinations thereof. Examples include benzyl, phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl. Hydrocarbon refers to any substituent comprised of hydrogen and carbon as the only elemental constituents.
  • carbocycle is intended to include ring systems in which the ring atoms are all carbon but of any oxidation state.
  • C3-C 1 0) carbocycle refers to both non-aromatic and aromatic systems, including such systems as cyclopropane, benzene, cyclopentene and cyclohexene;
  • Cs-Ci 2 ) carbopolycycle refers to such systems as norbornane, decalin, indane and naphthalene.
  • Carbocycle if not otherwise limited, refers to monocycles, bicycles and polycycles.
  • Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched or cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons. For the purpose of this application, alkoxy and lower alkoxy include methylenedioxy and ethyl enedioxy. Alkoxyalkyl refers to ether groups of from 3 to 8 atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an alkyl.
  • Alkoxyaryl refers to alkoxy substituents attached to an aryl, wherein the aryl is attached to the parent structure.
  • Arylalkoxy refers to aryl substituents attached to an oxygen, wherein the oxygen is attached to the parent structure.
  • Substituted arylalkoxy refers to a substituted aryl substituent attached to an oxygen, wherein the oxygen is attached to the parent structure.
  • Oxaalkyl refers to alkyl residues in which one or more carbons (and their associated hydrogens) have been replaced by oxygen. Examples include methoxypropoxy; 3,6,9-trioxadecyl; 2,6,7-trioxabicyclo[2.2.2]octane and the like.
  • the term oxaalkyl is intended as it is understood in the art [see Naming and Indexing of Chemical Substances for Chemical Abstracts, published by the American Chemical Society, 196, but without the restriction of 127(a)], i.e. it refers to compounds in which the oxygen is bonded via a single bond to its adjacent atoms (forming ether bonds); it does not refer to doubly bonded oxygen, as would be found in carbonyl groups.
  • thiaalkyl and azaalkyl refer to alkyl residues in which one or more carbons has been replaced by sulfur or nitrogen, respectively. Examples include ethylaminoethyl and methylthiopropyl.
  • acyl refers to formyl and to groups of 1, 2, 3, 4, 5, 6, 7 and 8 carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality.
  • One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like.
  • Lower-acyl refers to groups containing one to four carbons.
  • the double bonded oxygen, when referred to as a substituent itself is called "oxo".
  • Aryl and heteroaryl mean (i) a phenyl group (or benzene) or a monocyclic 5- or 6-membered heteroaromatic ring containing 1-4 heteroatoms selected from O, N, or S; (ii) a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-4 heteroatoms selected from O, N, or S; or (iii) a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-5 heteroatoms selected from O, N, or S.
  • Aryl, as understood herein, includes residues in which one or more rings are aromatic, but not all need be.
  • aromatic 6- to 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and fluorene and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.
  • Arylalkyl refers to a substituent in which an aryl residue is attached to the parent structure through alkyl. Examples are benzyl, phenethyl and the like. Heteroarylalkyl refers to a substituent in which a heteroaryl residue is attached to the parent structure through alkyl.
  • the alkyl group of an arylalkyl or a heteroarylalkyl is an alkyl group of from 1 to 6 carbons. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like.
  • Heterocycle means a cycloalkyl or aryl carbocycle residue in which from one to three carbons is replaced by a heteroatom selected from the group consisting of N, O and S.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • a heterocycle may be non-aromatic or aromatic. It is to be noted that heteroaryl is a subset of heterocycle in which the heterocycle is aromatic.
  • heterocyclic residues that fall within the scope of the invention include pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole (commonly referred to as methylenedioxyphenyl, when occurring as a substituent), morpholine, thiazole, pyridine (including 2-oxopyridine), pyridine N-oxide, pyrimidine, thiophene (i.e.
  • furan oxazole, oxazoline, oxazolidine, isoxazolidine, isoxazole, dioxane, azetidine, piperazine, piperidine, pyrrolidine, pyridazine, azepine, pyrazolidine, imidazole, imidazoline, imidazolidine, imidazolopyridine, pyrazine, thiazolidine, isothiazole, 1,2-thiazine- 1,1 -dioxide, quinuclidine, isothiazolidine, benzimidazole, thiadiazole, benzopyran, benzothiazole, benzotriazole, benzoxazole, tetrahydrofuran, tetrahydropyran, benzothiene, thiamorpholine, thiamorpholine sulfoxide, thiamorpholine sulfone, oxadiazole, triazo
  • An oxygen heterocycle is a heterocycle containing at least one oxygen in the ring; it may contain additional oxygens, as well as other heteroatoms.
  • Oxygen heterocycles found in the examples of the invention include tetrahydro furan, benzodioxole, morpholine, isoxazole and 2,6,7-trioxabicyclo[2.2.2]octane.
  • a sulphur heterocycle is a heterocycle containing at least one sulphur in the ring; it may contain additional sulphurs, as well as other heteroatoms.
  • a nitrogen heterocycle is a heterocycle containing at least one nitrogen in the ring; it may contain additional nitrogens, as well as other heteroatoms.
  • substituted refers to the replacement of one or more hydrogen atoms in a specified group with a specified radical.
  • substituted alkyl, aryl, cycloalkyl, heterocyclyl etc. refer to alkyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H atoms in each residue are replaced with halogen, haloalkyl, alkyl, acyl, alkoxyalkyl, hydroxyalkyl, carbonyl (i.e.
  • oxo is included among the substituents referred to in "optionally substituted", it will be appreciated by persons of skill in the art that, because oxo is a divalent radical, there are circumstances in which it will not be appropriate as a substituent (e.g. on phenyl). Additional substituents that are considered within the scope of the term, particularly for R 1 , are the are the residues of amino acids, amino acid amides, protected residues of aminoacids and their amides, and N-methylated (mono- or di-, as appropriate) amino acids and amino acid amides.
  • R 1 For the purpose of R 1 , the substituents alkyl, acyl, alkoxyalkyl, hydroxyloweralkyl, phenyl, heteroaryl, benzenesulfonyl, loweralkoxy, haloalkoxy, oxaalkyl, alkoxycarbonyl, alkoxycarbonylamino, carboxamido, alkylaminocarbonyl, amino, alkylamino, (alkyl)(aryl)aminoalkyl, alkylaminoalkyl, heterocyclylalkoxy, alkylthio, sulfonylamino, alkylsulfinyl, alkylsulfonyl, acylaminoalkyl, acylaminoalkoxy, acylamino, amidino, aryl, benzyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, phenoxy, benzyloxy,
  • a residue of an amino acid, amino acid amide refers to an amino acid etc. minus the functional groups that are considered part of the bond to the parent structure.
  • P- 143 illustrated below:
  • haloalkyl and “haloalkoxy” mean alkyl or alkoxy, respectively, substituted with one or more halogen atoms.
  • halogen means fluorine, chlorine, bromine or iodine. In one embodiment, halogen may be fluorine or chlorine.
  • the compounds of this invention can exist in radiolabeled form, i.e., the compounds may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • Radioisotopes of hydrogen, carbon, phosphorous, fluorine, and chlorine include 2 H, 3 H, 13 C, 14 C, 15 N, 35 S, 18 F, and 36 Cl, respectively.
  • Compounds that contain those radioisotopes and/or other radioisotopes of other atoms are within the scope of this invention.
  • Tritiated, i.e. 3 H, and carbon-14, i.e., 14 C, radioisotopes are particularly preferred for their ease in preparation and detectability.
  • Radiolabeled compounds of formula I of this invention and prodrugs thereof can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabeled compounds can be prepared by carrying out the procedures disclosed in the Examples and Schemes by substituting a readily available radiolabeled reagent for a non-radiolabeled reagent.
  • a compound is intended to include salts, solvates, co-crystals and inclusion complexes of that compound as well as any stereoisomeric form, or a mixture of any such forms of that compound in any ratio.
  • a compound as described herein including in the contexts of pharmaceutical compositions, methods of treatment, and compounds per se, is provided as the salt form.
  • the recitation "a compound of formula I" as depicted above, in which R 1 is imidazolyl would include imidazolium salts.
  • the term “compound of formula I” refers to the compound or a pharmaceutically acceptable salt thereof.
  • the compounds described herein may contain asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms.
  • Each chiral center may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • the present invention is meant to include all such possible isomers, in any ratio from racemic to optically pure forms.
  • Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
  • the prefix "rac" refers to a racemate.
  • solvate refers to a compound of Formula I in the solid state, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
  • a suitable solvent for therapeutic administration is physiologically tolerable at the dosage administered.
  • suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate.
  • solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions.
  • Inclusion complexes are described in Remington: The Science and Practice of Pharmacy 19 th Ed. (1995) volume 1, page 176-177, which is incorporated herein by reference. The most commonly employed inclusion complexes are those with cyclodextrins, and all cyclodextrin complexes, natural and synthetic, are specifically encompassed within the claims.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases.
  • salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
  • Suitable pharmaceutically acceptable anions for the compounds of the present invention include acetate, benzenesulfonate (besylate), benzoate, bicarbonate, bisulfate, carbonate, camphorsulfonate, citrate, ethanesulfonate, fumarate, gluconate, glutamate, glycolate, bromide, chloride, isethionate, lactate, maleate, malate, mandelate, methanesulfonate, mucate, nitrate, pamoate, pantothenate, phosphate, succinate, sulfate, tartrate, trifluoroacetate, p-toluenesulfonate, acetamidobenzoate, adipate, alginate, aminosalicylate, anhydromethylenecitrate, ascorbate, aspartate, calcium edetate, camphorate, camsylate, caprate, caproate, caprylate, cinnamate,
  • suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
  • a protecting group refers to a group, which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
  • the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
  • the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.
  • the starting materials are either commercially available, synthesized as described in the examples or may be obtained by the methods well known to persons of skill in the art.
  • PDE4 inhibitors have been shown to be effective therapeutic agents in clinical studies. For example, administration of cilomilast and roflumilast (PDE4 inhibitors) to patients suffering from asthma and COPD showed initially excellent results, although the effect of cilomilast disappeared on long-term trial [Lipworth, Lancet 365, 167-175 (2005)]. Genetic studies have clearly demonstrated an association between PDE4D and ischemic stroke (Gretarsdottir et al. 2003. Nature Genetics. 35, 1-8). L-454,560, a selective PDE4 inhibitor has been shown to improve learning in a rat model in vivo [Huang et al. Biochemical Pharmacology 73, 1971-1981 (2007)].
  • Rolipram another selective PDE4 inhibitor, has been shown to enhance cognition in multiple rodent models [Blokland et al., Current Pharmaceutical Design 12, 2511-2523 (2006)] as well as in primates [Rutten et al., 2008, Psychopharmacology 196, 643-648 (2008)]. Rolipram also improves the outcome in two separate studies in mice in vivo in models accepted by persons of skill in the art as predictive of utility in schizophrenia [Kanes et al., Neuroscience 144. 239-246 (2007); Davis and Gould, Behav.Neurosci. 119. 595-602 (2005)].
  • Rolipram has also been shown to exhibit a neuroprotective effect in a rat model of Huntington's disease [DeMarch et al. Neurobiol.Dis. 25, 266-273 (2007)]. This suggests that PDE4 modulators will be useful for treating many CNS disorders. Selective PDE4 inhibitors (e.g. rolipram) are also useful for treating bone loss [Yao et al., J.Musculoskelet.Neuronal Interact. 7. 119-130 (2007)].
  • a PDE4 inhibitor YM976 was shown to ameliorate the effects of experimentally-induced interstitial cystitis in rats, resulting in a decrease in the frequency of urination and an increase in the volume of urine at each time of urination [Kitta et al., BJU Int. 102. 1472-1476 (2008)].
  • the compounds, compositions and methods of the present invention may be useful in treating cancer.
  • Phosphodiesterase activity has been shown to be associated with hematological malignancies [Lerner et al., Biochem.J. 393, 21-41 (2006); Ogawa et al., Blood 99. 3390-3397 (2002)1.
  • the compounds may also be administered to overcome cognitive impairment induced by one or more of the following agents, alcohol, amphetamine, antipsychotic medication, anti-retroviral therapy, MDMA ( 3,4-methylenedioxy-N-methylamphetamine, cannabis, cocaine, delta-9 tetrahydrocannabinol, dexamphetamine, haloperidol, heroin and other opiates, ketamine and metamphetamine.
  • MDMA 3,4-methylenedioxy-N-methylamphetamine
  • cannabis cocaine, delta-9 tetrahydrocannabinol, dexamphetamine, haloperidol, heroin and other opiates, ketamine and metamphetamine.
  • the compounds, compositions and methods of the present invention may be employed as imaging agents and in other ways for diagnosis and/or treatment.
  • immobilization of compounds of the invention on solid support could be of utility for affinity purification and modification of compounds of the invention with chemically active groups may be used for protein labeling.
  • cholinesterase inhibitors e.g. tacrine, huperzine, donepezil
  • NMDA antagonists e.g. lanicemine, remacemide, neramexane, memantine
  • calpain inhibitors e.g. CEP-3122
  • antioxidants e.g. vitamin E, coenzyme QlO
  • agents that have shown clinical efficacy but whose mechanism is unclear e.g. dimebon).
  • Compounds of formula I may also be administered together with one or more of the following agents to improve cognition: amisulpride, atomoxetine, bromocryptine, buspirone, caffeine, chlorpromazine, clonidine, clozapine, diazepam, flumazenil, fluoxetine, galantamine, guanfacine, methylphenidate, idazoxan, modafinil, olanzapine, paroxetine, pergolide, phenserine, quetiapine, risperidone, rivastigmine, SGS742 and sulpiride.
  • the terms "methods of treating or preventing” mean amelioration, prevention or relief from the symptoms and/or effects associated with disorders.
  • preventing refers to administering a medicament beforehand to forestall or obtund an acute episode.
  • prevent is not an absolute term.
  • prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a condition, and this is the sense intended in applicants' claims.
  • treatment of a patient is intended to include prophylaxis.
  • mamal is used in its dictionary sense. Humans are included in the group of mammals, and humans would be the preferred subjects of the methods.
  • the cognitive impairment to be treated may arise from one or more of the following disorders, which may not in themselves be necessarily associated with PDE4 abnormality: acute pain, AD/HD - Attention deficit hyperactivity disorder, AIDS dementia complex, alcoholism, amphetamine addiction, amygdalo-hippocampectomy, anorexia nervosa, anterior parietal damage, antisocial behavior, antisocial personality disorder, anxiety, autism, basal ganglia lesions, bipolar disorder, borderline personality disorder, camptocormia, capgras syndrome, carcinoid syndrome, carotid endarterectomy surgery, chronic drug misuse, chronic fatigue syndrome, chronic occupational solvent encephalopathy, chronic pain, brain ischemia, coronary artery bypass surgery, critical illness requiring intensive care, dementia Alzheimer-type (DAT), dementia Lewy Body type, dementia of frontal type, dementia caused by ischemia, dental pain, developmental dyslexia, diabetes, dorsolateral frontal cortical compression, Down's Syndrome, drug abuse, dysexecutive syndrome,
  • a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically carriers thereof and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration. The most suitable route may depend upon the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and maybe prepared by any of the methods well known in the art of pharmacy.
  • Such methods include the step of bringing into association a compound of formula I or a pharmaceutically acceptable salt or solvate thereof ("active ingredient") with the carrier, which constitutes one or more accessory ingredients.
  • active ingredient a compound of formula I or a pharmaceutically acceptable salt or solvate thereof
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide sustained, delayed or controlled release of the active ingredient therein.
  • the pharmaceutical compositions may include a "pharmaceutically acceptable inert carrier", and this expression is intended to include one or more inert excipients, which include starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents, and the like. If desired, tablet dosages of the disclosed compositions may be coated by standard aqueous or nonaqueous techniques, "Pharmaceutically acceptable carrier” also encompasses controlled release means. [0050] Pharmaceutical compositions may also optionally include other therapeutic ingredients, anti-caking agents, preservatives, sweetening agents, colorants, flavors, desiccants, plasticizers, dyes, and the like.
  • composition may contain other additives as needed, including for example lactose, glucose, fructose, galactose, trehalose, sucrose, maltose, raffinose, maltitol, melezitose, stachyose, lactitol, palatinite, starch, xylitol, mannitol, myoinositol, and the like, and hydrates thereof, and amino acids, for example alanine, glycine and betaine, and peptides and proteins, for example albumen.
  • excipients for use as the pharmaceutically acceptable carriers and the pharmaceutically acceptable inert carriers and the aforementioned additional ingredients include, but are not limited to binders, fillers, disintegrants, lubricants, antimicrobial agents, and coating agents.
  • the dose range for adult humans is generally from 0.005 mg to 10 g/day orally. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of formula I which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity.
  • a dosage unit (e.g. an oral dosage unit) can include from, for example, 1 to 30 mg, 1 to 40 mg, 1 to 100 mg, 1 to 300 mg, 1 to 500 mg, 2 to 500 mg, 3 to 100 mg, 5 to 20 mg, 5 to 100 mg (e.g.
  • the agents can be administered, e.g., by intravenous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, topical, sublingual, intraarticular (in the joints), intradermal, buccal, ophthalmic (including intraocular), intranasaly (including using a cannula), or by other routes.
  • the agents can be administered orally, e.g., as a tablet or cachet containing a predetermined amount of the active ingredient, gel, pellet, paste, syrup, bolus, electuary, slurry, capsule, powder, granules, as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, via a micellar formulation (see, e.g. WO 97/11682) via a liposomal formulation (see, e.g., EP 736299,WO 99/59550 and WO 97/13500), via formulations described in WO 03/094886 or in some other form.
  • a micellar formulation see, e.g. WO 97/11682
  • a liposomal formulation see, e.g., EP 736299,WO 99/59550 and WO 97/13500
  • the agents can also be administered transdermally (i.e. via reservoir-type or matrix-type patches, microneedles, thermal poration, hypodermic needles, iontophoresis, electroporation, ultrasound or other forms of sonophoresis, jet injection, or a combination of any of the preceding methods (Prausnitz et al. 2004, Nature Reviews Drug Discovery 3:1 15)).
  • the agents can be administered locally, for example, at the site of injury to an injured blood vessel.
  • the agents can be coated on a stent.
  • the agents can be administered using high- velocity transdermal particle injection techniques using the hydrogel particle formulation described in U.S. 20020061336. Additional particle formulations are described in WO 00/45792, WO 00/53160, and WO 02/19989.
  • WO 96/11705 provides formulations suitable for transdermal administration.
  • the agents can be administered in the form a suppository or by other vaginal or rectal means.
  • the agents can be administered in a transmembrane formulation as described in WO 90/07923.
  • the agents can be administered non-invasively via the dehydrated particles described in U.S. 6,485,706.
  • the agent can be administered in an enteric-coated drug formulation as described in WO 02/49621.
  • the agents can be administered intranasaly using the formulation described in U.S. 5,179,079.
  • Formulations suitable for parenteral injection are described in WO 00/62759.
  • the agents can be administered using the casein formulation described in U.S. 20030206939 and WO 00/06108.
  • the agents can be administered using the particulate formulations described in U.S. 20020034536.
  • the agents alone or in combination with other suitable components, can be administered by pulmonary route utilizing several techniques including but not limited to intratracheal instillation (delivery of solution into the lungs by syringe), intratracheal delivery of liposomes, insufflation (administration of powder formulation by syringe or any other similar device into the lungs) and aerosol inhalation.
  • Aerosols e.g., jet or ultrasonic nebulizers, metered-dose inhalers (MDIs), and dry-Powder inhalers (DPIs)
  • MDIs metered-dose inhalers
  • DPIs dry-Powder inhalers
  • Aerosol formulations are stable dispersions or suspensions of solid material and liquid droplets in a gaseous medium and can be placed into pressurized acceptable propellants, such as hydrofluoroalkanes (HFAs, i.e. HFA-134a and HFA-227, or a mixture thereof), dichlorodifluoromethane (or other chlorofluorocarbon propellants such as a mixture of Propellants 11, 12, and/or 114), propane, nitrogen, and the like.
  • HFAs hydrofluoroalkanes
  • HFA-134a and HFA-227 or a mixture thereof
  • dichlorodifluoromethane or other chlorofluorocarbon propellants such as a
  • Pulmonary formulations may include permeation enhancers such as fatty acids, and saccharides, chelating agents, enzyme inhibitors (e.g., protease inhibitors), adjuvants (e.g., glycocholate, surfactin, span 85, and nafamostat), preservatives (e.g., benzalkonium chloride or chlorobutanol), and ethanol (normally up to 5% but possibly up to 20%, by weight). Ethanol is commonly included in aerosol compositions as it can improve the function of the metering valve and in some cases also improve the stability of the dispersion. Pulmonary formulations may also include surfactants which include but are not limited to bile salts and those described in U.S.
  • the surfactants described in U.S. 6,524,557 e.g., a C8-C 1 6 fatty acid salt, a bile salt, a phospholipid, or alkyl saccharide are advantageous in that some of them also reportedly enhance absorption of the compound in the formulation.
  • dry powder formulations comprising a therapeutically effective amount of active compound blended with an appropriate carrier and adapted for use in connection with a dry-Powder inhaler.
  • Absorption enhancers which can be added to dry powder formulations of the present invention include those described in U.S. 6,632,456.
  • WO 02/080884 describes new methods for the surface modification of powders. Aerosol formulations may include U.S.
  • Pulmonary formulations containing stable glassy state powder are described in U.S. 20020141945 and U.S. 6,309,671.
  • Other aerosol formulations are described in EP 1338272A1 WO 90/09781, U. S. 5,348,730, U.S. 6,436,367, WO 91/04011, and U.S. 6,294,153 and U.S. 6,290,987 describes a liposomal based formulation that can be administered via aerosol or other means.
  • Powder formulations for inhalation are described in U.S. 20030053960 and WO 01/60341.
  • the agents can be administered intranasally as described in U.S. 20010038824.
  • Solutions of medicament in buffered saline and similar vehicles are commonly employed to generate an aerosol in a nebulizer.
  • Simple nebulizers operate on Bernoulli's principle and employ a stream of air or oxygen to generate the spray particles.
  • More complex nebulizers employ ultrasound to create the spray particles. Both types are well known in the art and are described in standard textbooks of pharmacy such as Sprowls' American Pharmacy and Remington's The Science and Practice of Pharmacy.
  • Other devices for generating aerosols employ compressed gases, usually hydrofluorocarbons and chlorofluorocarbons, which are mixed with the medicament and any necessary excipients in a pressurized container, these devices are likewise described in standard textbooks such as Sprowls and Remington.
  • the agent can be incorporated into a liposome to improve half-life.
  • the agent can also be conjugated to polyethylene glycol (PEG) chains.
  • PEG polyethylene glycol
  • Methods for pegylation and additional formulations containing PEG-conjugates i.e. PEG-based hydrogels, PEG modified liposomes
  • the agent can be administered via a nanocochleate or cochleate delivery vehicle (BioDelivery Sciences International).
  • the agents can be delivered transmucosally (i.e. across a mucosal surface such as the vagina, eye or nose) using formulations such as that described in U.S. 5,204,108.
  • the agents can be formulated in microcapsules as described in WO 88/01165.
  • the agent can be administered intra-orally using the formulations described in U.S. 20020055496, WO 00/47203, and U.S. 6,495,120.
  • the agent can be delivered using nanoemulsion formulations described in WO 01/91728A2.
  • compounds of formula I may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.
  • the present invention relates to compounds exhibiting PDE4 enzyme inhibition, having the general formula I
  • X is CR 5
  • R 2 is pyrazolyl or substituted phenyl and R 3 is other than H.
  • R 1 is a substituted phenyl. In another embodiment, R 1 is phenyl and R 2 is pyrazolyl or substituted phenyl. In another embodiment, R 1 is substituted phenyl and R 2 is pyrazolyl or substituted phenyl.
  • R 1 is an unsubstituted heterocycle.
  • R 1 is a substituted heterocycle.
  • the heterocycle may be chosen from pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole, morpholine, thiazole, pyridine, pyridine N-oxide, pyrimidine, thiene, furan, oxazole, oxazoline, oxazolidine, isoxazolidine, isoxazole, dioxane, azetidine, piperazine, piperidine, pyrrolidine, pyridazine, azepine, pyrazolidine, imidazole, imidazoline, imidazolidine, purine, imidazolopyridine, pyrazine, thiazolidine
  • R 1 is an optionally substituted heterocycle chosen from pyrazole, benzodioxole, morpholine, thiazole, pyridine, pyridine N-oxide, pyrimidine, thiene, oxazolidine, isoxazole, azetidine, piperazine, pyrrolidine, imidazole, imidazolidine, imidazolopyridine, pyrazine, 1,2- thiazine- 1 , 1 -dioxide, benzimidazole, thiadiazole, benzotriazole, benzoxazole, oxadiazole, triazole, tetrazole, isoindole, pyrrolopyridine, triazolopyridine and their dihydro
  • the substituted phenyl or substituted heterocycle is substituted with a substituent chosen from halogen, haloalkyl, alkyl, acyl, alkoxyalkyl, hydroxyalkyl, carbonyl, phenyl, heteroaryl, benzenesulfonyl, hydroxy, alkoxy, haloalkoxy, oxaalkyl, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylamino, carboxyalkyl, alkoxycarbonylaminoalkyl, carboxyalkylcarbonylamino, carboxamido, aminocarbonyloxy, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonylalkyl, cyano, acetoxy, nitro, amino, alkylamino, dialkylamino, aminoalkyl, (alkyl)(aryl)aminoalkyl, alkylamin
  • One embodiment of compounds of the first genus are those in which R is methyl or fluoromethyl; R 6 is H; and M is -CH 2 - or -CH 2 O-.
  • R 2 is chosen from optionally substituted phenyl, optionally substituted monocyclic unsaturated heterocycle, unsubstituted bicyclic unsaturated heterocycle and fluoro-substituted bicyclic unsaturated heterocycle.
  • R 2 is chosen from optionally substituted phenyl, indole, benzodioxole, benzoxadiazole, benzodioxan, benzimidazole, oxadiazole, pyrazole, pyridine and pyridine N-oxide.
  • R 2 is chosen from meta- substituted phenyl, indole, benzodioxole, 2,2-difluorobenzodioxole, benzooxadiazole, benzimidazole, 5 -(pyridin-4-yl) [1,2,4] oxadiazole, 5 -(pyridin-4-yl) [1,3,4] oxadiazole, benzodioxan, 4-chloropyrazole, 4-(pyridin-4-yl)pyrazole, 6-chloropyridine, 3- (trifluoromethyl)pyrazole, and pyridine N-oxide.
  • R 2 is substituted phenyl:
  • R 7 is chosen from hydrogen, halogen, nitro, cyano, halo(Ci-Ce)alkyl, hydroxy, (Ci-Ce)alkoxy, (Ci-Ce)oxaalkyl, carboxy, (Ci-Ce)alkoxycarbonyl, aminocarbonyl (- CONH 2 ), (Ci-C 6 )alkylaminocarbonyl, acyl, hydroxy(Ci-Ce)alkyl, halo(Ci-Ce)alkoxy, amino(Ci-C6)alkyl, , amino, (Ci-C6)alkylamino, di[(Ci-C6)alkyl]amino, mercapto, (Ci- C 6 )alkylthio, (Ci-C 6 )alkylsulfinyl, (Ci-C 6 )alkylsulfonyl, (Ci-C 6 )alkylsulfonamido,
  • R 8 and R 13 are chosen independently from H and F.
  • R 8 and R 1 are H and R 7 is chosen from hydrogen, fluoro, chloro, bromo, nitro, cyano, acetyl, trifluoromethyl, methoxy, trifluoromethoxy, oxadiazolyl, tetrazolyl, methylthio, methanesulfinyl, methanesulfonyl, methansulfonamido, amino, methoxymethyl, hydroxyethyl, and morpholinyl.
  • R 1 is chosen from optionally substituted phenyl, optionally substituted five membered heteroaryl, optionally substituted six-membered heteroaryl, optionally substituted 4-7 membered non-aryl heterocycle, and optionally substituted fused bicycle.
  • R 1 may be chosen from optionally substituted phenyls; optionally substituted five membered heteroaryls selected from thiazoles, thiadiazoles, pyrazoles, oxadiazole, isoxazoles, triazoles, imidazoles, thiophenes, tetrazoles and oxazoles; optionally substituted six membered hereroaryls selected from pyridines, pyrimidines, pyridazinones, pyrimidinone, pyridinone, pyrazines and diazines; optionally substituted 5-and 6- membered non-aryl heterocyclics selected from tetrahydrothiophenes, piperazine, oxazolidinones, imidazolidinones, morpholines, piperidines, pyrrolidinones, pyrrolidinediones, pyrrolidines, piperidinones, piperidinediones and trio
  • R 3 is chosen from -CH 3 , -CH 2 CH 3 , -CF 3 , -CHF 2 and -CH 2 F;
  • R 5 is chosen from H, -F, -OH, -CH 3 , -OCH 3 , -CF 3 , -CN, -NH 2 and -C ⁇ CH;
  • phenyl and R 7 is chosen from H, halogen, nitro, acetyl, hydroxyethyl, -NH 2 , -
  • R 9 is chosen from H, (Ci-C 6 )alkyl, halo(Ci-C 6 )alkyl, (Ci-C 6 )alkoxycarbonyl, carboxy(Ci-Ce)alkyl, (Ci-C 6 )alkoxycarboxy(Ci-Ce)alkyl;
  • R 10 is H, (Ci-C 6 )alkyl, or taken together, or
  • R 9 and R 10 together form a heterocycle optionally substituted with (Ci-Ce)alkyl; p is 0 or 1, q is 0, 1 or 2,
  • R 11 is linear (Ci-C 6 )alkyl
  • R 12 is H or (Ci-C 6 )alkyl; or two adjacent substituents together form an optionally substituted fused heterocyclic ring.
  • R 5 is H
  • R 3 is -CH 3 and R 1 is substituted or unsubstituted pyrazole
  • compounds that have been tested and found active are those in which R 8 is -NO 2 or R 8 represents two adjacent substituents that form an optionally substituted, fused heterocycle.
  • R 3 is -CH 3
  • R 2 is -CF 3
  • R 1 is ⁇ / , the compound does not appear to be active in initial screening.
  • R 5 is H
  • R 3 is -CH 3
  • R 2 is -NO 2
  • R 1 is
  • the compound does not appear to be active in initial screening.
  • R 5 when R 5 is H, R 3 is -CH 3 , R 2 is -OCH 3 or -COCH 3 , and R 1 is , the compound does not appear to be active in initial screening.
  • One embodiment of compounds of the second genus has the formula
  • R la is phenyl, five-membered heteroaryl, six-membered heteroaryl, 4-7 membered non- aryl heterocycle or fused bicycle;
  • R . 1 1 5 3 is chosen from H, NO 2 , OH, NH 2 , and -NHSO 2 NH 2 ; or
  • R 27 is chosen from hydrogen, halogen, nitro, cyano, halo(Ci-Ce)alkyl, hydroxy, (Ci-
  • R 28 is chosen from H and F, or
  • R together with R forms a five-membered ring.
  • R 27 and R 28 represent a fused heterocycle at 3- and 4- ppoossiittiioonnss ssoo tthhaatt tthhee rreessiidduuee ffoorrmmsed from R 27 and R 28 together with the phenyl to which they are attached is chosen from:
  • R ,27 is chosen from halogen, nitro, acetyl, hydroxyethyl, amino, methylthio, trifluoromethyl, methoxymethyl, methoxycarbonyl, trifluoromethoxy, cyano and l,3,4-thiadiazol-2-yl, or taken together R 7 and R 8 are methylenedioxy or difluoromethylenedioxy.
  • R la may be chosen from a benzene ring, a triazole, a pyridine or pyridine-N-oxide, a pyrazole, a tetrahydrothiophene, an imidazole, a pyrimidine, a thiadiazole, and an imidazopyridine.
  • R is fluoro, H, CN or OH. In other embodiments, R 3 is methyl or fluoromethyl.
  • R 3 is methyl or fluorinated methyl
  • Y is CH or N
  • R 27a is chosen from halogen, cyano, acetyl, methylthio, nitro and trifluoromethyl
  • R 16 is
  • R . 17 , and R are independently chosen from H, (Ci-Ce)alkyl and halo(Ci- C 6 )alkyl;
  • R 19 is chosen from H, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, -[(C 1 -C 6 )alkyl]COOH, and -[(Ci-C6)alkyl]COO(Ci-C6)alkyl;
  • R 20 is chosen from a carboxylic acid, a carboxamide, a carboxylic ester, a primary, secondary or tertiary alcohol and a primary, secondary or tertiary amine.
  • Examples of a carboxylic acid, a carboxamide, a carboxylic ester, a primary, secondary or tertiary alcohol and a primary, secondary or tertiary amine include -COOH, -CONH 2 , -CONHCH 3 , -CON(CH 3 ) 2 , -COOCH 3 , -CH 2 OH, -CH(CH 3 )OH, -C(CHs) 2 OH, -CH 2 NH 2 , -CH(CH 3 )NH 2 and -C(CH 3 ) 2 NH 2 .
  • X is CH, CF or N->O; M is -CH 2 - or -S-; R 2 7a a is chosen from chloro, cyano, acetyl and methylthio; and R is chosen from -NR C(O)NR R
  • Y is
  • R 16 is -NR 17 C(K))NR 18 R 19 .
  • R 16 is -NR 17 C(O)NR 18 R 19 and R 17 , R 18 and R 19 are all hydrogen.
  • R 15 is chosen from H, NO 2 , OH, NH 2 , and -NHSO 2 NH 2 ; or R 15 together with R 14 forms methylene dioxy.
  • R 3 is chosen from -CH 3 , -CH 2 CH 3 , -CF 3 , -CHF 2 and - CH 2 F.
  • R 5 is chosen from H, -F, -OH, -CH 3 , -OCH 3 , -CF 3 , -CN, -NH 2 and -C ⁇ CH.
  • R 7 is chosen from H, halogen, nitro, acetyl, hydroxyethyl, -NH 2 , -SCH 3 , methoxycarbonyl, -SOCH 3 , -SO 2 CH 3 , -OCH 3 , -OCF 3 , -CN, -CF 3 , -CH 2 OCH 3 and oxadiazole, and a fused heterocycle at 3- and 4- positions.
  • R 5 may be fluoro, H, CN or OH. In certain embodiments of the compounds I, R may be methyl or fluoromethyl. (Fluoromethyl is intended to include CHF 2 , CH 2 F and CF 3 .)
  • the invention in a composition aspect, is all active compounds of formula I except those that are in the public's possession.
  • a search of the literature indicates that certain compounds in which X is N, R 3 is methyl, M is CH 2 , R 2 is a five-membered ring heterocycle, and R 1 is a substituted tetralin are known.
  • certain compounds in which X is N, R is methyl, M is CH 2 , R 1 is a five-membered ring heterocycle, and R 2 is a substituted tetralin are known.
  • the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures.
  • Generally compounds of the Formula I, where R 2 is a substituted aryl / heteroaryl and the two biaryl groups are linked by a C-C bond, may be prepared from appropriately functionalized alkoxy-aryl ether derivatives containing desirable functionalities W, where W may for example be CH, N, COH, CF, etc (Route A, Scheme Al).
  • the biaryl portion can be constructed first, typically via Suzuki or Stille coupling (Gl -> G2).
  • Y halogen or OSO2R (OTf, ONf) and the other reagent would be R2- B(OR)2 or R2-SnR3' or vise versa, where R2 -halogen is coupled with Gl containing boronate/boronic acid or trialkyltin as Y.
  • A is a carbon derived substituent, e.g. CH3, CH2OH, CO2R", CN etc. these groups are converted to provide intermediate G3 where D is either a halogen or OTf, ONf, or OCOOR” (carbonate) such that substituent (Rl) is introduced by employing a transition-metal catalyzed coupling reactions such as Suzuki, Stille or Negishi reaction.
  • Rl which may be aryl, heterocyclic, acyclic, aliphatic, or any other desirable variety of functionality, to the central aromatic ring (Ar) by a wide rage of tether groups M.
  • the central aromatic ring (Ar) may be a biaryl ring system with a R2 group already attached, or the R2 group may be attached subsequent to that of Rl .
  • the linker group M may be a linear chain of one or more atoms consisting of C, N, O, or S.
  • the linker group M may also consist of functionalities including, but not limited to amide, sulfonamide, sulfone, or ketone.
  • halogen allows susceptibility of the aromatic halogen for nucleophilic displacement.
  • ArI group containing NO2, CO2R, ketone, CN etc. would allow formation of aryl-M-aryl(heteroaryl) intermediates.
  • the linker group M may also be subject to further elaboration.
  • sulfides may be oxidized to sulfoxides and sulfones and amines may be subjected to alkylation or reductive amination.
  • Well known synthetic transformations can be used to create tether groups M such as ether amide, sulfonamide, and the like.
  • the functional group location in the precursor Ar and Rl groups can be used to dictate the nature and type of the linkage (e.g. alternative ethers), as mentioned above.
  • aldehyde functionality can subsequently be transformed into a suitable transition-metal catalyzed coupling reaction partner.
  • the aldehye could be used for Wittig reaction forming olefin or CH2CH2 linkage to incorporate Rl.
  • substituent "A” can be various types of carbonyl (aldehyde or ketone) or imine groups.
  • Rl-MgX organometallic Rl group
  • aldehyde G9 CHO
  • Similar types of transformations could be employed by one skilled in the art if G9 contained A : ketone or imine.
  • the C-C bond forming reaction between the Ar and Rl groups could be accomplished by displacement of a leaving group on the Rl by a nucleophile present in the tether region M (Scheme G4) of G 12.
  • M-Z is CH2-halide or CH2-O-sulfonate
  • Rl fragment can be introduced via formation of ether linkage. This allows attachment of Rl to the central aromatic ring by spacers (M) of varying lengths and compositions. (Scheme A4)
  • the Rl group could also be assembled form an acyclic intermediate to form a heterocylic or heteroaromatic ring.
  • these chemistries include formation of 5-membered heteroaryls such as oxadiazole, thiadiazole, triazole (G 17) form acyl hydrazide (G 16); thiazole from 2-halo-ketone or dipolar cycloaddition reactions from olefin or acetylic group to form 5-membered heterocycles or 5-membered heteroaryls (Gl 8) [Scheme A5].
  • 6-membered heteroaryl or heterocyclic rings could be formed using Diels-Alder or hetero- Diels-Alder chemistries using appropriately substituted alkyl aryl ether bearing either a dienophile or a diene functionalities.
  • the necessary acyclic precursors could be synthesized by standard methods according to previously described intermediates (e.g. aldehyde, alkyl halide) schemes.
  • Rl and R2 The diverse selection of substituents present in Rl and R2 could be formed by standard functional group transformations that are well know in the art. Some of these include formation of amide, sulfonamide, ureas, imidazolone, oxazolones, carbamates from the R2, R3, or Ar ring fragments bearing appropriate amine, carboxylic acid, alcohol, or phenol groups.
  • a particularly useful aromatic ring functionalization technique, in which either the R2 or Rl rings can be employed, is the nucleophilic displacement of ortho-halo N-containing aromatic rings (G20, scheme A7). Examples of ring substrates useful in this type of transformation include 2-halo-pyridine, 2-halo- pyrimidine and 2-halo-imidazole.
  • nucleophiles (R) useful in this type of transformation include amines (primary, secondary, acyclic, or cyclic), alcohols, phenols, NH-containing heterocycle groups (imidazole, or pyrrazole) groups capable of performing nucleophilic displacement.
  • Rl group contains additional functional groups, such as amine, ester/acid /alcohols many of which may have be masked or protected during the previous chemistries, these could be used for further functional group manipulations.
  • additional functional groups such as amine, ester/acid /alcohols many of which may have be masked or protected during the previous chemistries
  • Rl functionalities may be achieved using well established synthetic procedures including, but not limited to, alkylation, reductive amination, nucleophilic displacement, cyclization, saponification, and oxidation/reduction.
  • ArI mono-cyclic may be further transformed to a bi-cyclic ring.
  • Examples of such ring transformations may be represented by elaboration of pyridine derivatives to imidazo[l,2-a]pyridine and imidazo[l,5-a]pyridine. These functional group manipulations and bicyclic ring elaborations maybe accomplished at any chemically suitable point in the synthesis prior to or post incorporation of R2 or other synthetic transformations.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound as described above.
  • Methods of the invention parallel the compositions and formulations.
  • the methods comprise administering to a patient in need of treatment a therapeutically effective amount of a compound according to the invention.
  • the present invention also provides a method for inhibiting phosphodiesterase 4.
  • Buffer A containing 50 mM Tris, pH 8.0, 16 mM MgCl 2 and 80 mM KCl is prepared and stored at room temperature.
  • Buffer B containing 50 mM Tris, pH 8.0 is prepared and stored at toom temperature.
  • Stock solutions of the following reagents are prepared in Buffer B and stored at -20 0 C: Adenosine-5 '-triphosphate (ATP), cyclic adenosine-5' -monophosphate (cAMP), phosphoenolpyruvate (PEP) and NADH.
  • ATP Adenosine-5 '-triphosphate
  • cAMP cyclic adenosine-5' -monophosphate
  • PEP phosphoenolpyruvate
  • An assay mix is prepared by mixing Buffer A, trichloroethylphosphine (TCEP), ATP, PEP, NADH, myokinase (MK), pyruvate kinase (PK), lactate dehydroganese (LDH) and PDE4 to a final volume of 20 mL, which is enough for a single 96-well assay plate.
  • Assay mix 180 ⁇ L
  • test article (10 ⁇ L ) in 1: 1 DMSO/H2O mixture is pre-incubated at room temperature for 10 min. The enzymatic reaction is initiated by addition of cAMP (10 ⁇ L).
  • Final concentration of all components in the assay (200 ⁇ L/well) are as follows: 10 mM MgCl 2 , 50 mM KCl, 5 mM TCEP, 2.5% DMSO, 0.4 mM NADH, 1 mM PEP, 0.04 mM ATP, 5 units MK, 1 unit PK, 1 unit LDH and appropriate amount of PDE4.
  • Reaction progress curves are monitored in a plate reader capable of measuring light absorbance at 340 nM. A decrease in light absorbance at 340 nm is due to oxidation of NADH.
  • Positive controls containing no test article and negative controls containing no test article and no cAMP are included on every assay plate. Reaction rates are determined from the slopes of the linear portions of the progress curves. All data is percent normalized with respect to controls and presented as percent inhibition.
  • the activity of PDE4 inhibitors decribed in the present invention was also measured using in an ex- vivo assay measuring leukotriene E4 (LTE4) in human whole blood after Sephadex stimulation.
  • LTE4 leukotriene E4
  • the anti- inflammatory activity of therapeutic agents of the present invention is demonstrated by the inhibition of eosinophil activation as measured by sephadex bead stimulated LTE4 production in whole human blood.
  • 356 ⁇ l of heparinized human whole blood (Vacutainer tube #6480) is added to wells of a 96 well plate.
  • Persons of skill in the art accept that positive results in PDE4 models are predictive of therapeutic utility as discussed above.
  • reaction mixture was then heated to 60 0 C for 15 minutes, and allowed to cool naturally to room temperature, and stirred for 16 hours.
  • the reaction mixture was then extracted with two portions of diethyl ether, and the combined ethereal layers washed with brine, dried over magnesium sulfate, filtered through a layer of celite and concentrated.
  • the resultant mixture was stirred at the same temperature for 10 minutes, and to it was added a solution of 4-fluorobenzonitrile (18.2 mmol; 2 eq.) in tetrachloroethane and aluminum chloride (10.0 mmol; 1.1 eq.).
  • the reaction was heated to 110 0 C for 5 hours, and allowed to cool to room temperature and stir for 16 hours.
  • the reaction mixture was added 10 mL of 3N HCl, and the resultant mixture was heated to 90 0 C for 1 hour, and cooled to room temperature.
  • the pH was adjusted with 6N NaOH to 11-12, and extracted with dichloromethane. The organics were washed with a brine solution, dried over magnesium sulfate, and filtered.
  • the reaction was stirred at 70 0 C for 16 hours, and cooled to room temperature.
  • the reaction was diluted with water, and extracted with two portions of ethyl acetate.
  • the combined organics were washed with three portions of water, brine, dried over magnesium sulfate, and filtered through celite.
  • reaction mixture was cooled to 0 0 C, diluted with water (3 mL), basified with ammonium hydroxide solution (28%), filtered, washed with water dried to afford 0.08 g (81%) of l-[4-(3'-chloro-2-fluoro-6-methoxy-biphenyl-3- ylmethyl)-phenyl]-lH-tetrazole (P-404) as off-white solid.
  • the mixture was heated to 90 0 C for 18 hours and then cooled to room temperature. After water (30 mL) and 5% aqueous potassium carbonate (30 mL) were added, the aqueous portion was extracted with ethyl acetate (2 x 35 mL) and the organic portions were combined, washed brine (30 mL), dried (magnesium sulfate) and concentrated.
  • the aqueous layer was extracted with ethyl acetate (100 mL) and the organic extracts were combined.
  • the organic solution was washed with water (200 mL) and brine (200 mL), dried over sodium sulfate, filtered, and the solvent removed under vacuum .
  • the residue was purified by flash silica gel column chromatography (10-33% acetone in dichloromethane), triturated in diethyl ether (5 mL), filtered, washed with hexanes (5 mL) and diethyl ether (2 mL) to give P-252 (190 mg, 15 % yield) as a beige powder.
  • reaction mixture was diluted with water, neutralized with 6N HCl, extracted with ethyl acetate, washed with water and brine, and dried over Na2SO4. After it was concentrated in vacuo, the residue was purified by a chromatography on silica gel to yield N-[5-(3'-chloro-2-fluoro- 6-methoxy-biphenyl-3-ylmethyl)-pyridin-2-yl]-methanesulfonamide (P-258) (25 mg, 32%).
  • reaction mixture was bubbled with nitrogen gas for 5 minutes. Then the yellow reaction mixture was stirred at 80 0 C. After overnight stirring the reaction mixture was cooled to room temperature and concentrated in-vacuo. The residue was diluted in EtOAc (2OmL) and washed with water (30 mL). The aqueous layer was extracted with EtOAc (2 x 2OmL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4 and concentrated in-vacuo.
  • the mixture was heated to 90 0 C for 16 hours and then cooled to room temperature.
  • the palladium catalyst was removed via filtration and to the filtrate was added IM HCl (50 mL) and water (50 mL).
  • the aqueous portion was Extracted with ethyl acetate(2 x 75 mL), the organic portions were combined, washed with brine (75 mL), dried (MgSO 4 ) and concentrated.
  • the crude material was purified by column chromatography utilizing 75% EtOAc/hexanes as the eluent to produce 207 mg of the free base as a dark orange oil in 82% yield.
  • the free base was treated with 4.0 M HCl in 1,4-dioxane (1.0 mL) and stirred for 3 hours at room temperature.
  • the reaction mixture was treated with diethyl ether (4 mL) and the solid was collected via suction filtration.
  • the aqueous wash was extracted into ethyl acetate (50 mL), and the organic extracts combined.
  • the ethyl acetate solution was washed with 1 N aqueous hydrochloric acid (50 mL), water (2 x 50 mL), and brine (50 mL), dried over sodium sulfate, and the solvent removed under vacuum.
  • the resultant solid was triturated with diethyl ether (5 mL), filtered, washed with diethyl ether (2 x 3 mL), and dried to give product (P-448) (109.2 mg, 51% yield).
  • [00175] 1 -[4-(3'-Chloro-6-methoxy-biphenyl-3-sulfonyl)-phenyl]-3 -ethyl-urea (P- 450).
  • To the solution was added 290 uL of 10% v/v (30% w/w hydrogen peroxide in water) in acetic acid.
  • R2 R4 Cl, 4-pyr ⁇ dyl
  • the mixture was degassed with nitrogen for 30 minutes and then added tetrakis(triphenylphosphine)palladium(0) (5.17 g, 4.48 mmol).
  • the mixture was heated to 60 0 C for 4 hours and then the palladium catalyst was filtered off.
  • To the filtrate were added water (100 mL) and a saturated ammonium chloride solution (150 mL). After extracting with ethyl acetate (3 x 100 mL), the organic portions were combined, washed with brine (150 mL), dried (MgSO 4 ) and concentrated.
  • the mixture was heated to 190 0 C in a Biotage Initiator microwave reactor for 1 hour.
  • the mixture was quenched with water (50 mL) and a saturated ammonium chloride solution (50 mL) followed by an extraction with ethyl acetate (2 x 100 mL).
  • the organic portions were combined, dried (MgSO 4 ) and concentrated.
  • the residue was purified via column chromatography utilizing 15% acetone/dichloromethane as the eluent. After a failed recrystallization attempt with dichlormethane/hexanes, 41 mg of P- 389 as a viscous, yellow oil in 13% yield.
  • the mixture was heated to 190 0 C in a Biotage Initiator microwave reactor for 1 hour.
  • the mixture was quenched with water (30 mL) and a saturated ammonium chloride solution (30 mL) followed by an extraction with ethyl acetate (2 x 60 mL).
  • the organic portions were combined, dried (MgSO 4 ) and concentrated.
  • the residue was purified via column chromatography utilizing 20% ethyl acetate/hexanes as the eluent to produce 20 mg of P-396 as a viscous, yellow oil in 7% yield.
  • R1 H, Me, CHF2, CF3 I-62
  • R2 Cl, CH3CO, CN, NO2, Br, fused heterocycle
  • reaction mixture was diluted with ethyl acetate (80 mL) and washed with water (2 x 40 mL), brine and dried over Na 2 SO 4 . After removal of solvent, the residue was triturated with Et 2 O (20 mL) to give 2.18 g of product; Yield: 81 %.
  • R1 H, Me, CHF2, CF3
  • R2 Cl, CH3CO, CN, NO2, Br, fused heterocycle
  • R2 R3 substituted aryl groups
  • the reaction mixture was stirred at rt. After overnight stirring the reaction mixture was quenched with water (20 mL). The mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 and concentrated in- vacuo. The crude was purified by silica gel column chromatography, eluted with dichloromethane/MeOH (200:5) to produce 77.1 mg (39% yield) of the product (P-479) as a pale yellow solid.
  • R1 H, Me, CHF2, CF3
  • R2 Cl, CH3CO, CN, NO2, Br, fused heterocycle
  • Y H, F, OH, NH2, CN, OCH3, OEt
  • R1 H, Me, CHF2, CF3
  • R2 Cl, CH3CO, CN, NO2, Br, fused heterocycle
  • R1 H, Me, CHF2, CF3
  • R2 Cl, CH3CO, CN, NO2, Br, fused heterocycle
  • R3 substituted aryl groups
  • Reaction mixture was diluted with water (40 ml) and extracted with ethyl acetate (2 x 40 mL). The combined organic phase was washed with water (2 x 30 mL), brine and dried over Na 2 SO 4 . After removal of solvent, the residue was purified by silica gel column chromatography with ethyl acetate/hexane as eluent to give 39 mg g of the product (P-015) Yield: 40 %.
  • the reaction was heated to 108 0 C and stirred at this temperature overnight.
  • the reaction was diluted with ethyl acetate (200 mL) and water (200 mL). The layers were separated and the aqueous layer extracted with ethyl acetate (200 mL). The organic extracts were combined, washed with water (400 mL) and brine (300 mL), dried over sodium sulfate, filtered, and the solvent removed under vacuum to give crude product.
  • the crude material was purified by flash silica gel column chromatography (0-5% methanol in dichloromethane) to give I-89a (1.53 g, 77% yield) as a beige powder.
  • Reaction mixture was concentrated to a 1/3, and then it was diluted with ethyl acetate (300 ml) and washed with 0.6 N sodium hydrogen sulfate solution (300 ml), water (2x 150 ml), brine and dried over Na 2 SO 4 . After removal of solvent, 7.75 g of product (1-100) was obtained as oil. Yield: 100 %.
  • the reaction was heated to 80 0 C over night. Additional palladium acetate (8.9 mg, 0.039 mmol) and triphenylphosphine (20.6 mg, 0.0788 mmol) was added and the mixture was stirred an additional night at 80 0 C. The solvent was removed under vacuum and taken up in ethyl acetate (50 mL). The organic solution was washed with saturated aqueous ammonium chloride (2 x 75 mL), water (3 x 75 mL) water, and the combined aqueous layers were extracted with ethyl acetate (50 mL).
  • the organic suspension was washed with saturated aqueous ammonium chloride (2 x 50 mL), 1 N aqueous sodium hydroxide (3 x 50 mL), water (50 mL), and brine (50 mL), decolorized over activated carbon, dried over sodium sulfate, and removed under vacuum to give crude product.
  • the product was purified by flash silica gel column chromatography eluting with 1% methanol in dichloromethane to give P-014 (102.1 mg, 36% yield) as an off white powder.
  • the aqueous wash was extracted with ethyl acetate (2 x 150 mL), and all the ethyl acetate extracts combined, washed with saturated aqueous ammonium chloride (3 x 300 mL), water (2 x 300 mL), and brine (300 mL), dried over sodium sulfate and the solvent removed under vacuum to give 1-110 as a yellow oil (11.39 g; 77% yield) which solidified to a greasy yellow solid.
  • the reaction was stirred at 80 0 C under argon for 20 h.
  • the reaction was cooled to room temperature, concentrated, and H2O (60 mL) and dichloromethane (80 mL) were added.
  • the layers were separated and the aqueous was extracted with dichloromethane (2 x 40 mL).
  • the combined organic extracts were dried with Na 2 SO 4 , filtered, and concentrated.
  • the residue was purified by silica gel column chromatography using 10% ethyl acetate/hexanes as eluent to afford 1.69 g (65%) of 1-81 as a white solid.
  • the reaction was stirred at 80 0 C under argon for 18 h.
  • the reaction was cooled to room temperature, concentrated, and diluted with H 2 O and dichloromethane (40 mL each).
  • the organic layer was separated and the aqueous was extracted with dichloromethane (2 x 25 mL).
  • the combined organic extracts were dried with Na 2 SO 4 , filtered, and concentrated.
  • the residue was purified by preparative TLC using 3% MeOH in dichloromethane to afford 0.051 g (51%) of P-019 as a light brown viscous liquid.
  • the reaction was stirred at 80 0 C under argon for 18 h.
  • the reaction was cooled to room temperature, concentrated, and diluted with H2O and dichloromethane (40 mL each).
  • the organic layer was separated and the aqueous was extracted with dichloromethane (2 x 25 mL).
  • the combined organic extracts were dried with Na 2 SO 4 , filtered, and concentrated.
  • the residue was purified by silica gel column chromatography using 1 : 1 dichloromethane-hexanes then dichloromethane to afford 0.08 g (71%) of P-021 as a light brown viscous liquid.
  • the reaction mixture was slowly warmed to room temperature and stirred for 20 h.
  • the reaction was poured on to crushed ice-water and extracted with ethyl acetate (2 x 40 mL).
  • the combined organic extracts were dried with Na2SO4, filtered, and concentrated.
  • the residue was purified by silica gel column chromatography using dichloromethane to afford 0.027 g (47%) of P-030 as a viscous liquid.
  • the reaction mixture was slowly warmed to room temperature and stirred for 20 h.
  • the reaction was poured on to crushed ice-water and extracted with ethyl acetate (2 x 40 mL).
  • the combined organic extracts were dried with Na 2 SO4, filtered, and concentrated.
  • the residue was purified by silica gel column chromatography using dichloromethane to afford 0.047 g (77%) of P-038 as a viscous liquid.
  • the reaction was stirred at 80 0 C under argon for 20 h.
  • the reaction was cooled to room temperature, concentrated, and H 2 O and dichloromethane (40 mL each) were added.
  • the organic layer was separated and the aqueous layer was extracted with dichloromethane (2 x 25 mL).
  • the combined organic extracts were dried with Na 2 SO 4 , filtered, and concentrated.
  • the residue was purified by silica gel column chromatography using 1 : 1 dichloromethane-hexanes then dichloromethane to afford 1.36 g (86%) of 1-117 as a light yellow solid.
  • the reaction was diluted with saturated aqueous ammonium chloride (100 mL) and the suspension was extracted with ethyl acetate (100 mL).
  • the purple organic extract was washed with water (3 x 50 mL) water, saturated aqueous ammonium chloride (3 x 50 mL), brine (50 mL) dried over anhydrous sodium sulfate, and the solvent removed under vacuum to afford 476.1 mg of 1-119 as a purple powder in 72% yield.
  • triphenylphosphine (33.5 mg, 0.128 mmol), solid potassium carbonate (265 mg, 1.92 mmol) and a mixture of ethanol and water (1: 1, 1 mL) was added, and the reaction was stirred under nitrogen for 10 min.
  • To the reaction was added palladium(II)acetate, and the reaction heated to 80 0 C with stirring overnight.
  • the solvent was removed under vacuum and the residue was suspended in saturated aqueous ammonium chloride (50 mL), and the aqueous slurry was extracted with ethyl acetate (2 x 50 mL).
  • the reaction was cooled to room temperature and diluted with ethyl acetate (150 mL).
  • the organic solution was washed with water (5 x 100 mL), brine (100 mL), dried over sodium sulfate, and the solvent removed under vacuum.
  • the residue was purified by flash silica gel column chromatography eluting with 0-2% methanol in dichloromethane followed by flash silica gel column chromatography with 50% ethyl acetate in hexanes, and the residue wash dissolved in ethyl acetate (10 mL).
  • the organic solution was washed with water (2 x 10 mL) and the wash extracted with ethyl acetate (2 x 10 mL).
  • triphenylphosphine (58.8 mg, 0.112 mmol), solid potassium carbonate (463 mg, 3.36 mmol), ethanol (1 mL), water (1 mL), and palladium(II)acetate (25.1 mg, 0.112 mmol) under nitrogen.
  • the reaction was stirred at 100 0 C for 18 h.
  • the solvent was removed under vacuum and the residue taken up in ethyl acetate (50 mL).
  • the organic solution was washed with saturated aqueous ammonium chloride (50 mL), the residual palladium was filtered, and the organic extract was washed with water (2 x 50 mL), brine (50 mL), dried over sodium sulfate, and removed under vacuum.
  • the crude product was purified by flash silica gel column chromatography eluting with 5% methanol in dichloromethane, followed by a second flash silica gel column eluting with 5% acetone in dichloromethane.
  • the solid thus obtained was recrystallized in diethyl ether (5 mL) and hexanes (10 mL), filtered, and washed with hexanes (5 mL) to give P-058 (65 mg; 21% yield) as a white powder.
  • P-084 Synthesis of l-(6-Methoxy-3'-trifluoromethoxy-biphenyl-3-ylmethyl)-lH- [l,2,4]triazole (P-084).
  • P-084 was synthesized from 1-110 (200 mg, 0.746 mmol) and 3-trifluoromethoxyphenylboronic acid (169 mg, 0.821 mmol) by the same reaction conditions that were used for P-081. After removal of the solvent under vacuum, the residue was diluted with ethyl acetate (30 mL) and washed with water (30 mL).
  • the aqueous wash was extracted with ethyl acetate (30 mL), and the combined organic extracts were washed with water (2 x 50 mL), saturated aqueous ammonium chloride (50 mL), brine (50 mL), dried over sodium sulfate, decolorized over activated charcoal, and the solvent removed under vacuum.
  • the residue was purified by flash silica gel column chromatography eluting with 5% acetone in dichloromethane to give P-084 as a yellow oil (187.3 mg, 54% yield).
  • P-085 [00335] Synthesis of 1 -(6-Methoxy-3 '-methylsulfanyl-biphenyl-3 -ylmethyl)- 1 H- [l,2,4]triazole (P-085).
  • P-085 was synthesized from 1-110 (200 mg, 0.746 mmol) and 3-methylsulfanylphenylboronic acid (138 mg, 0.821 mmol) using the same conditions as P-081. The reaction was worked up by diluting with ethyl acetate (30 mL) and washing with water (30 mL).
  • the aqueous wash was extracted with ethyl acetate (30 mL), and the organic extractions combined, washed with water (2 x 50 mL), saturated aqueous ammonium chloride (50 mL), brine (50 mL), decolorized with activated carbon, dried over sodium sulfate, and the solvent removed under vacuum.
  • the residue was purified by flash silica gel column chromatography eluting with 5% acetone in dichloromethane to give P-085 (117.1 mg, 50% yield) as a yellow gum.
  • the organic extracts were washed with water (3 x 30 mL), saturated aqueous ammonium chloride (2 x 30 mL), brine (30 mL), decolorized with activated carbon, dried over sodium sulfate, and the solvent removed under vacuum.
  • the product was purified by flash silica gel column chromatography eluting with 0-25% acetone in dichloromethane, and was run on a silica gel preparatory plate eluting with 1% acetone in dichloromethane for three developments to obtain P-108 (49.0 mg, 19% yield) as a yellow oil.
  • the reaction mixture was stirred for 10 min at 0 0 C, then added to a suspension of Cu(I)CN (0.031 g, 1.2 mmol) in water (0.5 mL) and toluene (1 mL) over 5 min at 0 0 C.
  • the reaction mixture was slowly warmed to room temperature, stirred at room temperature for 2 h, then at 50 0 C for 30 min.
  • the reaction was extracted with dichloromethane (3 x 5 mL), and the combined organic extracts were washed with brine, dried with Na 2 SO4, filtered, and concentrated under vacuum.
  • the residue was purified by silica gel column chromatography using 1 : 1 dichloromethane-hexanes then dichloromethane to afford 1-123 (0.201 g, 61% yield) as white solid.

Abstract

La présente invention concerne un genre de composés biaryle contenant au moins un cycle supplémentaire. Les composés sont des inhibiteurs de PDE4 utiles pour le traitement et la prévention d'un accident vasculaire cérébral, d'un infarctus du myocarde et de maladies et troubles inflammatoires cardiovasculaires. Les composés répondent à la formule générale I : (la formule doit être insérée ici). Un mode de réalisation particulier est (une seconde formule doit être insérée ici).
PCT/US2008/084193 2007-11-21 2008-11-20 Inhibiteurs de pde4 biaryle pour traiter une inflammation WO2009067600A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2722582A CA2722582A1 (fr) 2007-11-21 2008-11-20 Inhibiteurs de pde4 biaryle pour traiter une inflammation
EP08851045A EP2222638A2 (fr) 2007-11-21 2008-11-20 Inhibiteurs de pde4 biaryle pour traiter une inflammation
CN2008801251758A CN102089279A (zh) 2007-11-21 2008-11-20 用于治疗炎症的联芳基pde4抑制剂
JP2010535064A JP2011505341A (ja) 2007-11-21 2008-11-20 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤
PCT/US2008/084193 WO2009067600A2 (fr) 2007-11-21 2008-11-20 Inhibiteurs de pde4 biaryle pour traiter une inflammation
AU2008326381A AU2008326381B2 (en) 2007-11-21 2008-11-20 Biaryl PDE4 inhibitors for treating inflammation
IL205881A IL205881A0 (en) 2008-11-20 2010-05-20 Biaryl pde4 inhibitors for treating inflammation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98955107P 2007-11-21 2007-11-21
US60/989,551 2007-11-21
PCT/US2008/084193 WO2009067600A2 (fr) 2007-11-21 2008-11-20 Inhibiteurs de pde4 biaryle pour traiter une inflammation

Publications (2)

Publication Number Publication Date
WO2009067600A2 true WO2009067600A2 (fr) 2009-05-28
WO2009067600A3 WO2009067600A3 (fr) 2009-07-30

Family

ID=41650335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/084193 WO2009067600A2 (fr) 2007-11-21 2008-11-20 Inhibiteurs de pde4 biaryle pour traiter une inflammation

Country Status (6)

Country Link
EP (1) EP2222638A2 (fr)
JP (1) JP2011505341A (fr)
CN (1) CN102089279A (fr)
AU (1) AU2008326381B2 (fr)
CA (1) CA2722582A1 (fr)
WO (1) WO2009067600A2 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059838A2 (fr) * 2008-11-20 2010-05-27 Decode Genetics Ehf Inhibiteurs de pde4 sélectifs pour la forme longue de pde4 pour traiter une inflammation et éviter des effets secondaires
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
US8338405B2 (en) 2006-02-28 2012-12-25 Dart Neuroscience Llc Therapeutic piperazines
CN103012255A (zh) * 2011-09-21 2013-04-03 天津康鸿医药科技发展有限公司 罗氟司特晶型化合物、其制备方法、组合物及应用
CN103012408A (zh) * 2012-11-28 2013-04-03 中国科学院广州生物医药与健康研究院 依匹斯汀的合成方法
JP2013530241A (ja) * 2010-06-30 2013-07-25 アイロンウッド ファーマシューティカルズ， インコーポレイテッド ｓＧＣ刺激薬
JP2013532734A (ja) * 2010-08-04 2013-08-19 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾患を治療するための組成物及び方法
JP2014503537A (ja) * 2010-12-24 2014-02-13 メルク・シャープ・エンド・ドーム・ベー・フェー Ｎ置換アゼチジン誘導体
US8791267B2 (en) 2007-11-21 2014-07-29 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders
EP2784068A1 (fr) * 2012-02-20 2014-10-01 Xu, Jiangping Inhibiteur de phosphodiestérase-4 capable d'éviter des vomissements
WO2014158998A1 (fr) * 2013-03-14 2014-10-02 Dart Neuroscience, Llc Composés de pyridine et de pyrazine substitués en tant qu'inhibiteurs de la pde4
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
WO2015136473A1 (fr) 2014-03-14 2015-09-17 Wockhardt Limited Procédé de préparation de (2s, 5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate de sodium
WO2016064445A1 (fr) 2014-10-24 2016-04-28 Biotherapeutics, Inc. Agents thérapeutiques à base de lancl2
EP3165224A1 (fr) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Utilisation d'inhibiteurs de pde4 pour la prophylaxie et/ou la thérapie de la dyslipoproteinémie et des troubles apparentés
WO2017089347A1 (fr) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
WO2020219615A1 (fr) * 2019-04-23 2020-10-29 Tetra Discovery Partners, Inc. Dérivés de 3-hydroxy-2-phényl-6-(pyrazol-4-ylméthyl)pyridine utilisés en tant qu'inhibiteurs de pde4d
WO2021127472A1 (fr) 2019-12-20 2021-06-24 Landos Biopharma, Inc. Ligands de la protéine 2 de type lanthionine c, cellules préparées avec ceux-ci, et thérapies les utilisant
US11078192B2 (en) 2016-07-05 2021-08-03 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
US11197891B2 (en) 2017-11-30 2021-12-14 Landos Biopharma, Inc. Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
WO2022057928A1 (fr) 2020-09-18 2022-03-24 上海医药集团股份有限公司 Composé carbonyle hétérocyclique et son utilisation
WO2022119090A1 (fr) * 2020-12-01 2022-06-09 한국과학기술연구원 Dérivés de biphénylpyrrolidine et de biphényldihydroimidazole permettant d'inhiber l'activité du récepteur 5-ht7 de la sérotonine, et composition pharmaceutique le comprenant comme principe actif
US11384048B2 (en) 2017-12-29 2022-07-12 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
RU2802185C2 (ru) * 2013-03-14 2023-08-22 Дарт Нейросайенс (Кайман) Лтд. Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110041253B (zh) * 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
CN112374984A (zh) * 2020-11-06 2021-02-19 苏州求索生物科技有限公司 一种2-溴-4-羟基苯甲醚的制备工艺

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675118A2 (fr) * 1994-03-29 1995-10-04 Eisai Co., Ltd. Dérivés de biphényle, procédé pour leur préparation et leur utilisation comme médicaments
WO1996016058A1 (fr) * 1994-11-23 1996-05-30 Neurogen Corporation Composes aminomethyle aryle, ligands selectifs d'un sous-type de recepteur de dopamine
WO1997032853A1 (fr) * 1996-03-08 1997-09-12 Novartis Ag Composes triaryles
WO1999031062A1 (fr) * 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Nouveaux composes de pyridine
WO2000014083A1 (fr) * 1998-09-09 2000-03-16 Inflazyme Pharmaceuticals Ltd. Δ-LACTONES η-PHENYL-SUBSTITUEES, LEURS ANALOGUES, ET LEURS UTILISATIONS
EP1227086A1 (fr) * 1999-10-22 2002-07-31 Takeda Chemical Industries, Ltd. Alcools de phenyl-1-(1h-imidazol-4-yl) substitues en position 1, procede de preparation et utilisation de ces derniers
WO2002072009A2 (fr) * 2001-03-07 2002-09-19 Maxia Pharmaceuticals, Inc. Derives heterocycliques pour le traitement du cancer et d'autres maladies proliferatives
WO2003094845A2 (fr) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Ligands du recepteur de la thyroide a base de pyridine
WO2004084824A2 (fr) * 2003-03-24 2004-10-07 Merck & Co., Inc. Heterocycles a 6 elements a substitution biaryle en tant que bloqueurs des canaux sodiques
WO2004092140A1 (fr) * 2003-04-03 2004-10-28 Merck & Co., Inc. Pyrazoles biaryle substitue utilises en tant que bloqueurs de canaux sodiques
WO2004093799A2 (fr) * 2003-04-18 2004-11-04 Bristol-Myers Squibb Company Ligands de recepteur des hormones thyroidiennes
WO2005047270A2 (fr) * 2003-11-10 2005-05-26 Merck & Co., Inc. Triazoles substitues utilises en tant que bloqueurs du canal sodique
WO2005051298A2 (fr) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
WO2006056854A1 (fr) * 2004-11-23 2006-06-01 Pfizer Products Inc. Composes et derives de dibenzyl amine
WO2006066978A1 (fr) * 2004-12-23 2006-06-29 Galderma Research & Development Nouveaux ligands qui modulent les recepteurs rar, et leur utilisation en medecine et en cosmetique
WO2006083477A2 (fr) * 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Composes utilises pour des etats inflammatoires et immunitaires
WO2007079186A2 (fr) * 2005-12-30 2007-07-12 Merck & Co., Inc. Inhibiteurs de la cetp
WO2008001959A1 (fr) * 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Nouveau dérivé hétérocyclique 6-5 bicyclique et utilisation médicale de celui-ci

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3778430D1 (en) * 1986-06-20 1992-05-27 Idemitsu Kosan Co Polycarbonate.
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5594141A (en) * 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
WO1997003967A1 (fr) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Composes aromatiques substitues et leur utilisation pharmaceutique
FR2754260B1 (fr) * 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU3363599A (en) * 1998-03-26 1999-10-18 Max-Planck Institut Fur Biochemie Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2005030206A1 (fr) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Derives d'aryl-1,3-azole et procedes permettant d'inhiber l'activite de l'heparanase
BRPI0418148A (pt) * 2003-12-25 2007-04-17 Takeda Pharmaceutical composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
HUE032640T2 (en) * 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
NZ569327A (en) * 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
CN103980151A (zh) * 2006-08-09 2014-08-13 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物
JP2010522214A (ja) * 2007-03-21 2010-07-01 アルミラル， エセ．アー． アデノシンレセプターアンタゴニストとしての置換ピリミジン
EP2628727A3 (fr) * 2007-11-21 2013-12-25 Decode Genetics EHF Inhibiteurs de PDE4 biaryle pour le traitement de troubles pulmonaires et cardiovasculaires
FR2932180B1 (fr) * 2008-06-04 2012-08-10 Centre Nat Rech Scient Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675118A2 (fr) * 1994-03-29 1995-10-04 Eisai Co., Ltd. Dérivés de biphényle, procédé pour leur préparation et leur utilisation comme médicaments
WO1996016058A1 (fr) * 1994-11-23 1996-05-30 Neurogen Corporation Composes aminomethyle aryle, ligands selectifs d'un sous-type de recepteur de dopamine
WO1997032853A1 (fr) * 1996-03-08 1997-09-12 Novartis Ag Composes triaryles
WO1999031062A1 (fr) * 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Nouveaux composes de pyridine
WO2000014083A1 (fr) * 1998-09-09 2000-03-16 Inflazyme Pharmaceuticals Ltd. Δ-LACTONES η-PHENYL-SUBSTITUEES, LEURS ANALOGUES, ET LEURS UTILISATIONS
EP1227086A1 (fr) * 1999-10-22 2002-07-31 Takeda Chemical Industries, Ltd. Alcools de phenyl-1-(1h-imidazol-4-yl) substitues en position 1, procede de preparation et utilisation de ces derniers
WO2002072009A2 (fr) * 2001-03-07 2002-09-19 Maxia Pharmaceuticals, Inc. Derives heterocycliques pour le traitement du cancer et d'autres maladies proliferatives
WO2003094845A2 (fr) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Ligands du recepteur de la thyroide a base de pyridine
WO2004084824A2 (fr) * 2003-03-24 2004-10-07 Merck & Co., Inc. Heterocycles a 6 elements a substitution biaryle en tant que bloqueurs des canaux sodiques
WO2004092140A1 (fr) * 2003-04-03 2004-10-28 Merck & Co., Inc. Pyrazoles biaryle substitue utilises en tant que bloqueurs de canaux sodiques
WO2004093799A2 (fr) * 2003-04-18 2004-11-04 Bristol-Myers Squibb Company Ligands de recepteur des hormones thyroidiennes
WO2005047270A2 (fr) * 2003-11-10 2005-05-26 Merck & Co., Inc. Triazoles substitues utilises en tant que bloqueurs du canal sodique
WO2005051298A2 (fr) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
WO2006056854A1 (fr) * 2004-11-23 2006-06-01 Pfizer Products Inc. Composes et derives de dibenzyl amine
WO2006066978A1 (fr) * 2004-12-23 2006-06-29 Galderma Research & Development Nouveaux ligands qui modulent les recepteurs rar, et leur utilisation en medecine et en cosmetique
WO2006083477A2 (fr) * 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Composes utilises pour des etats inflammatoires et immunitaires
WO2007079186A2 (fr) * 2005-12-30 2007-07-12 Merck & Co., Inc. Inhibiteurs de la cetp
WO2008001959A1 (fr) * 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Nouveau dérivé hétérocyclique 6-5 bicyclique et utilisation médicale de celui-ci

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NG. PH. BUU-HOI, AND MICHEL. SY: "The Pfitzinger Reaction with Ketones Derived from o-Hydroxydiphenyl" JOURNAL OF ORGANIC CHEMISTRY, vol. 21, no. 1, 1956, pages 136-138, XP002517829 *
R. FUSCO, AND F. SANNICOLO: "Rearrangement of arylhydrazones of aromatic and arylaliphatic carbonyl compounds to biphenyl derivatives. 3" JOURNAL OF ORGANIC CHEMISTRY, vol. 46, no. 1, 1981, pages 83-89, XP002517830 *
S. YOGI, K. HOKAMA, S. TAKAYOSHI, O. TSUGE: "Synthesis of Imido-Substituted 3,8-Diphenyl-1,2-diazacycloocta-2,4,6,8-te traenes and their Thermolysis" BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 60, February 1987 (1987-02), pages 731-735, XP002517828 *
See also references of EP2222638A2 *
SRINIVASARAO ARULANANDA BABU, MAKOTO YASUDA, AND AKIO BABA: "In(III)-Mediated Chemoselective Dehydrogenative Interaction of ClMe2SiH with Carboxylic Acids: Direct Chemo- and Regioselective Friedel?Crafts Acylation of Aromatic Ethers" ORGANIC LETTERS, vol. 9, no. 3, 12 January 2007 (2007-01-12), pages 405-408, XP002517831 *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501745B2 (en) 2006-02-28 2013-08-06 Dart Neuroscience (Cayman) Ltd. Piperazine PDE4 inhibitors and uses thereof
US8338405B2 (en) 2006-02-28 2012-12-25 Dart Neuroscience Llc Therapeutic piperazines
US8791267B2 (en) 2007-11-21 2014-07-29 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders
WO2010059838A3 (fr) * 2008-11-20 2010-12-02 Decode Genetics Ehf Inhibiteurs de pde4 sélectifs pour la forme longue de pde4 pour traiter une inflammation et éviter des effets secondaires
WO2010059838A2 (fr) * 2008-11-20 2010-05-27 Decode Genetics Ehf Inhibiteurs de pde4 sélectifs pour la forme longue de pde4 pour traiter une inflammation et éviter des effets secondaires
JP2013530241A (ja) * 2010-06-30 2013-07-25 アイロンウッド ファーマシューティカルズ， インコーポレイテッド ｓＧＣ刺激薬
US10189809B2 (en) 2010-06-30 2019-01-29 Ironwood Pharmaceuticals, Inc. SGC stimulators
US8748442B2 (en) 2010-06-30 2014-06-10 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9617197B2 (en) 2010-08-04 2017-04-11 University Of Virginia Patent Foundation Compositions and methods for treating inflammatory diseases
JP2013532734A (ja) * 2010-08-04 2013-08-19 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾患を治療するための組成物及び方法
CN103338767A (zh) * 2010-08-04 2013-10-02 弗吉尼亚大学专利基金会 治疗炎症性疾病的组合物和方法
CN103338767B (zh) * 2010-08-04 2018-06-22 弗吉尼亚大学专利基金会 治疗炎症性疾病的组合物和方法
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
JP2014503537A (ja) * 2010-12-24 2014-02-13 メルク・シャープ・エンド・ドーム・ベー・フェー Ｎ置換アゼチジン誘導体
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
CN103012255A (zh) * 2011-09-21 2013-04-03 天津康鸿医药科技发展有限公司 罗氟司特晶型化合物、其制备方法、组合物及应用
EP2784068A1 (fr) * 2012-02-20 2014-10-01 Xu, Jiangping Inhibiteur de phosphodiestérase-4 capable d'éviter des vomissements
EP2784068A4 (fr) * 2012-02-20 2014-10-22 Xu Jiangping Inhibiteur de phosphodiestérase-4 capable d'éviter des vomissements
JP2015503570A (ja) * 2012-02-20 2015-02-02 徐 江平ＸＵ，Ｊｉａｎｇｐｉｎｇ 嘔吐反応を防止することができるホスホジエステラーゼ４阻害剤
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
US9499497B2 (en) 2012-11-20 2016-11-22 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
CN103012408B (zh) * 2012-11-28 2015-02-04 中国科学院广州生物医药与健康研究院 依匹斯汀的合成方法
CN103012408A (zh) * 2012-11-28 2013-04-03 中国科学院广州生物医药与健康研究院 依匹斯汀的合成方法
US9573937B2 (en) 2013-03-14 2017-02-21 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as PDE4 inhibitors
AU2018202148B2 (en) * 2013-03-14 2019-10-31 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as PDE4 inhibitors
CN105143207A (zh) * 2013-03-14 2015-12-09 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
RU2802185C2 (ru) * 2013-03-14 2023-08-22 Дарт Нейросайенс (Кайман) Лтд. Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
US9120770B2 (en) 2013-03-14 2015-09-01 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as PDE4 inhibitors
US11279691B2 (en) 2013-03-14 2022-03-22 Dart Neuroscience Llc Substituted pyridine and pyrazine compounds as PDE4 inhibitors
TWI672292B (zh) * 2013-03-14 2019-09-21 開曼群島商達特神經科學（開曼）有限責任公司 作為ｐｄｅ４抑制劑之經取代之吡啶及吡化合物
AU2014241430B2 (en) * 2013-03-14 2018-04-26 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as PDE4 inhibitors
TWI623523B (zh) * 2013-03-14 2018-05-11 達特神經科學（開曼）有限責任公司 作為ｐｄｅ４抑制劑之經取代之吡啶及吡化合物
US9040692B2 (en) 2013-03-14 2015-05-26 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as PDE4 inhibitors
EP3345902A1 (fr) 2013-03-14 2018-07-11 Dart NeuroScience (Cayman) Ltd Composés de pyridine et de pyrazine substitués en tant qu'inhibiteurs de pde4
CN108299400A (zh) * 2013-03-14 2018-07-20 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
WO2014158998A1 (fr) * 2013-03-14 2014-10-02 Dart Neuroscience, Llc Composés de pyridine et de pyrazine substitués en tant qu'inhibiteurs de la pde4
RU2668073C2 (ru) * 2013-03-14 2018-09-26 Дарт Нейросайенс (Кайман) Лтд. Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
WO2015136473A1 (fr) 2014-03-14 2015-09-17 Wockhardt Limited Procédé de préparation de (2s, 5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate de sodium
US10201538B2 (en) 2014-10-24 2019-02-12 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
WO2016064445A1 (fr) 2014-10-24 2016-04-28 Biotherapeutics, Inc. Agents thérapeutiques à base de lancl2
US10493072B2 (en) 2014-10-24 2019-12-03 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
US10682349B2 (en) 2014-10-24 2020-06-16 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
US10849895B2 (en) 2014-10-24 2020-12-01 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
EP3757099A1 (fr) 2014-10-24 2020-12-30 Landos Biopharma, Inc. Agents thérapeutiques à base de lanthionine synthétase c de type 2
US11571419B2 (en) 2014-10-24 2023-02-07 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
US10028950B2 (en) 2014-10-24 2018-07-24 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
EP3165224A1 (fr) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Utilisation d'inhibiteurs de pde4 pour la prophylaxie et/ou la thérapie de la dyslipoproteinémie et des troubles apparentés
WO2017089347A1 (fr) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
US11078192B2 (en) 2016-07-05 2021-08-03 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
US11197891B2 (en) 2017-11-30 2021-12-14 Landos Biopharma, Inc. Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
US11384048B2 (en) 2017-12-29 2022-07-12 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
US11104660B2 (en) 2019-04-23 2021-08-31 Tetra Discovery Partners, Inc. PDE4D inhibitors
WO2020219615A1 (fr) * 2019-04-23 2020-10-29 Tetra Discovery Partners, Inc. Dérivés de 3-hydroxy-2-phényl-6-(pyrazol-4-ylméthyl)pyridine utilisés en tant qu'inhibiteurs de pde4d
US11117881B2 (en) 2019-12-20 2021-09-14 Landos Biopharma, Inc. Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
US11377437B2 (en) 2019-12-20 2022-07-05 Landos Biopharma, Inc. Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same
WO2021127472A1 (fr) 2019-12-20 2021-06-24 Landos Biopharma, Inc. Ligands de la protéine 2 de type lanthionine c, cellules préparées avec ceux-ci, et thérapies les utilisant
WO2022057928A1 (fr) 2020-09-18 2022-03-24 上海医药集团股份有限公司 Composé carbonyle hétérocyclique et son utilisation
WO2022119090A1 (fr) * 2020-12-01 2022-06-09 한국과학기술연구원 Dérivés de biphénylpyrrolidine et de biphényldihydroimidazole permettant d'inhiber l'activité du récepteur 5-ht7 de la sérotonine, et composition pharmaceutique le comprenant comme principe actif

Also Published As

Publication number Publication date
AU2008326381A1 (en) 2009-05-28
EP2222638A2 (fr) 2010-09-01
CN102089279A (zh) 2011-06-08
AU2008326381B2 (en) 2014-10-23
CA2722582A1 (fr) 2009-05-28
JP2011505341A (ja) 2011-02-24
WO2009067600A3 (fr) 2009-07-30

Similar Documents

Publication Publication Date Title
AU2008326381B2 (en) Biaryl PDE4 inhibitors for treating inflammation
US8791267B2 (en) Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders
ES2521016T3 (es) Derivados de piridina di-sustituida como agentes anticancerosos
US11649233B2 (en) Halo-allylamine SSAO/VAP-1 inhibitor and use thereof
WO2010059838A2 (fr) Inhibiteurs de pde4 sélectifs pour la forme longue de pde4 pour traiter une inflammation et éviter des effets secondaires
US9440954B2 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
JP2010111624A (ja) Ｔｔｋ阻害作用を有するインダゾール誘導体
AU2008326385B2 (en) Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders
AU2006276231A1 (en) HIV reverse transcriptase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880125175.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08851045

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 205881

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010535064

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 586281

Country of ref document: NZ

Ref document number: 2008326381

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 20107013784

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2242/KOLNP/2010

Country of ref document: IN

Ref document number: 2008851045

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2008326381

Country of ref document: AU

Date of ref document: 20081120

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2722582

Country of ref document: CA